Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

| More on:
A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.

Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:

Gentrack Group Ltd (ASX: GTK)

According to a note out of Bell Potter, its analysts have retained their buy rating on this utilities software company's shares with a trimmed price target of $13.20. This follows the release of a half year result this week that was below expectations. Bell Potter notes that project revenues within utilities dragged slightly against a strong prior period and the phasing of contract wins. Nevertheless, it remains positive on the future and is bullish on Gentrack's ability to maintain customer win momentum. It expects this to support high NRR revenues, which will flow onto ARR. The Gentrack share price is trading at $10.57 on Wednesday afternoon.

ResMed Inc. (ASX: RMD)

A note out of Goldman Sachs reveals that its analysts have retained their conviction buy rating and $49.30 price target on this sleep disorder treatment company's shares. This follows news that Apnimed has had success with its phase 3 trial of a sleep apnoea pill. Goldman Sachs isn't concerned and feels that the share price weakness caused by the news has been an overreaction. It believes that Apnimed's AD109's pill is unlikely to displace CPAP as first line therapy in treating OSA. Particularly given that its initial target opportunity are patients who have refused or have failed CPAP. In light of this, Goldman Sachs remains as bullish as ever on ResMed and its long term zoutlook. The ResMed share price is fetching $38.80 at the time of writing.

TechnologyOne Ltd (ASX: TNE)

Analysts at UBS have retained their buy rating on this enterprise software company's shares with an improved price target of $42.20. According to the note, the broker was impressed with TechnologyOne's half year results. It highlights that annual recurring revenue grew strongly and was in line with its expectations. Whereas its profits were comfortably ahead of its estimates for the half. Combined with its strong net revenue retention rate and ultra low churn levels, it believes the result supports its bullish view on the long term growth outlook of the company. The Technology One share price is trading at $38.46 this afternoon.

Motley Fool contributor James Mickleboro has positions in ResMed and Technology One. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Gentrack Group, Goldman Sachs Group, ResMed, and Technology One. The Motley Fool Australia has positions in and has recommended Gentrack Group and ResMed. The Motley Fool Australia has recommended Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A few gold nullets sit on an old-fashioned gold scale, representing ASX gold shares.
Broker Notes

Up 300% since August, why this surging ASX gold stock could keep racing higher

A leading broker forecasts more strong outperformance from this rocketing ASX gold stock.

Read more »

A colourfully dressed young skydiver wearing heavy gold gloves smiles and gives a thumbs up as he falls through the sky.
Broker Notes

Bell Potter says this ASX silver stock has 'a sky full of upside'

This exciting stock could be a high risk, high reward pick according to the broker.

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Broker Notes

These 2 ASX All Ords shares tripled in value last year. Can they keep going?

Both of these ASX shares more than tripled their market capitalisations in 2025.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Morgans says these ASX 200 shares can rise 20%+

The broker says these shares could offer major upside.

Read more »

Three women athletes lie flat on a running track as though they have had a long hard race where they have fought hard but lost the event.
Broker Notes

Brokers rate 2 ASX All Ords rippers of 2025: Is their phenomenal run over?

Both of these ASX shares more than tripled in value last year.

Read more »

a woman puts her hand to her chin and looks to the side deep in thought as though pondering something significant.
Broker Notes

2 ASX 200 gold shares to buy and 1 to sell: experts

After exceptional share price growth for 2 years, experts say investors need to choose their gold stocks carefully.

Read more »

Keyboard button with the word sell on it, symbolising the time being right to sell ASX stocks.
Resources Shares

ASX 200 materials was the best sector of 2025 but it's time to sell these 3 shares: broker

Morgan Stanley has just updated its ratings and 12-month price targets on 3 ASX 200 mining shares.

Read more »